WallStreetZenWallStreetZen

NASDAQ: TGTX
Tg Therapeutics Inc Stock

$17.36-0.61 (-3.39%)
Updated Feb 3, 2023
TGTX Price
$17.36
Fair Value Price
$18.17
Market Cap
$2.52B
52 Week Low
$3.48
52 Week High
$18.31
P/E
-9.81x
P/B
25.11x
P/S
159.43x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.03M
Earnings
-$238.68M
Gross Margin
90.6%
Operating Margin
-4,582.51%
Profit Margin
-4,749.8%
Debt to Equity
1.17
Operating Cash Flow
-$239M
Beta
1.91
Next Earnings
Feb 27, 2023
Ex-Dividend
N/A
Next Dividend
N/A

TGTX Overview

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TGTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TGTX ($17.36) is undervalued by 4.47% relative to our estimate of its Fair Value price of $18.17 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
TGTX ($17.36) is not significantly undervalued (4.47%) relative to our estimate of its Fair Value price of $18.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TGTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TGTX due diligence checks available for Premium users.

Be the first to know about important TGTX news, forecast changes, insider trades & much more!

TGTX News

Valuation

TGTX fair value

Fair Value of TGTX stock based on Discounted Cash Flow (DCF)
Price
$17.36
Fair Value
$18.17
Undervalued by
4.47%
TGTX ($17.36) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TGTX ($17.36) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TGTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TGTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-9.81x
Industry
10.7x
Market
15.09x

TGTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
25.11x
Industry
5.11x
TGTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TGTX's financial health

Profit margin

Revenue
$94.0k
Net Income
-$35.8M
Profit Margin
-38,104.3%
TGTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TGTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$217.9M
Liabilities
$117.4M
Debt to equity
1.17
TGTX's short-term assets ($182.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TGTX's short-term assets ($182.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TGTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TGTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$34.5M
Investing
-$3.0M
Financing
$275.0k
TGTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TGTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
TGTX$2.52B-3.39%-9.81x25.11x
VTYX$2.49B+1.79%3.74x6.48x
XENE$2.45B+2.22%-20.10x3.25x
MYOV$2.61B-0.04%-14.07x-4.68x
CORT$2.62B-0.61%22.52x5.53x

Tg Therapeutics Stock FAQ

What is Tg Therapeutics's quote symbol?

NASDAQ: TGTX) Tg Therapeutics trades on the NASDAQ under the ticker symbol TGTX. Tg Therapeutics stock quotes can also be displayed as NASDAQ: TGTX.

If you're new to stock investing, here's how to buy Tg Therapeutics stock.

What is the 52 week high and low for Tg Therapeutics (NASDAQ: TGTX)?

(NASDAQ: TGTX) Tg Therapeutics's 52-week high was $18.31, and its 52-week low was $3.48. It is currently -5.19% from its 52-week high and 398.85% from its 52-week low.

How much is Tg Therapeutics stock worth today?

(NASDAQ: TGTX) Tg Therapeutics currently has 145,341,967 outstanding shares. With Tg Therapeutics stock trading at $17.36 per share, the total value of Tg Therapeutics stock (market capitalization) is $2.52B.

Tg Therapeutics stock was originally listed at a price of $225.00 in May 3, 2010. If you had invested in Tg Therapeutics stock at $225.00, your return over the last 12 years would have been -92.28%, for an annualized return of -19.22% (not including any dividends or dividend reinvestments).

How much is Tg Therapeutics's stock price per share?

(NASDAQ: TGTX) Tg Therapeutics stock price per share is $17.36 today (as of Feb 3, 2023).

What is Tg Therapeutics's Market Cap?

(NASDAQ: TGTX) Tg Therapeutics's market cap is $2.52B, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Tg Therapeutics's market cap is calculated by multiplying TGTX's current stock price of $17.36 by TGTX's total outstanding shares of 145,341,967.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.